Literature DB >> 35446177

Revisiting the use of proton magnetic resonance spectroscopy in distinguishing between primary and secondary malignant tumors of the central nervous system.

Milena K Farche1, Natalia O Fachinetti1, Luciana Rp da Silva2, Larissa A Matos3, Simone Appenzeller4, Fernando Cendes5, Fabiano Reis1.   

Abstract

BACKGROUND AND
PURPOSE: Conventional magnetic resonance images (MRI) has limitations in distinguishing primary from secondary brain tumors. Proton magnetic resonance spectroscopy (1H-MRS) allows evaluation of the concentration of metabolites in a brain lesion and, hence, better characterization of the tumor. Considering that an accurate diagnosis determines the choice of treatment, our purpose was to assess the usefulness of spectroscopy data for differentiating between primary and secondary brain neoplasms.
MATERIALS AND METHODS: We undertook a retrospective analysis of 61 MRI and 1H-MRS images of patients with histologically confirmed tumors (30 primary tumors and 31 metastatic tumors). The metabolite ratios of Cho/Cr and NAA/Cr at short TE were determined from spectroscopic curves, with a single voxel positioned in the enhancing tumor. Additional variables analyzed along with the metabolites, like as age and gender, allowed the construction of a logistic regression model to predict the tumor's nature. The statistical analysis was done using the R software (version 4.0.3 R Core Team, 2020).
RESULTS: The mean NAA/Cr and Cho/Cr ratios were higher in secondary tumors, with a good correlation between NAA/Cr and Cho/Cr (r = 0.61). The mean age of patients with primary tumors was lower than for secondary tumors (43.9 vs 55.9, respectively). Receiver operating characteristic analysis yielded a cut-off value of 0.4 for the NAA/Cr ratio with an accuracy of 73.8%, a sensitivity of 73.3% and a specificity of 74.2% in predicting metastatic tumors.
CONCLUSION: The model was reasonable in predicting the nature of the tumor and provides an additional tool for analyzing brain tumors.

Entities:  

Keywords:  Brain; glioma; magnetic resonance spectroscopy

Mesh:

Substances:

Year:  2022        PMID: 35446177      PMCID: PMC9513916          DOI: 10.1177/19714009221083145

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  27 in total

Review 1.  A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors.

Authors:  W Hollingworth; L S Medina; R E Lenkinski; D K Shibata; B Bernal; D Zurakowski; B Comstock; J G Jarvik
Journal:  AJNR Am J Neuroradiol       Date:  2006-08       Impact factor: 3.825

Review 2.  Magnetic resonance spectroscopy of the brain: a review of physical principles and technical methods.

Authors:  Michael H Buonocore; Richard J Maddock
Journal:  Rev Neurosci       Date:  2015       Impact factor: 4.353

3.  Primary sarcoma of the leptomeninges: unusual presentation and previously undescribed neuroimaging features.

Authors:  João Vitor Gerdulli Tamanini; Fabio Rogerio; Laisson de Moura Feitoza; Thales André Caricati; Luciano Souza Queiroz; Fabiano Reis
Journal:  Arq Neuropsiquiatr       Date:  2019-09-23       Impact factor: 1.420

4.  Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging.

Authors:  S Wang; S Kim; S Chawla; R L Wolf; D E Knipp; A Vossough; D M O'Rourke; K D Judy; H Poptani; E R Melhem
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-17       Impact factor: 3.825

5.  Adult brain tumors: clinical applications of magnetic resonance spectroscopy.

Authors:  Lara A Brandão; Mauricio Castillo
Journal:  Neuroimaging Clin N Am       Date:  2013-05-10       Impact factor: 2.264

6.  Comparison of Multivendor Single-Voxel MR Spectroscopy Data Acquired in Healthy Brain at 26 Sites.

Authors:  Michal Považan; Mark Mikkelsen; Adam Berrington; Pallab K Bhattacharyya; Maiken K Brix; Pieter F Buur; Kim M Cecil; Kimberly L Chan; David Y T Chen; Alexander R Craven; Koen Cuypers; Michael Dacko; Niall W Duncan; Ulrike Dydak; David A Edmondson; Gabriele Ende; Lars Ersland; Megan A Forbes; Fei Gao; Ian Greenhouse; Ashley D Harris; Naying He; Stefanie Heba; Nigel Hoggard; Tun-Wei Hsu; Jacobus F A Jansen; Alayar Kangarlu; Thomas Lange; R Marc Lebel; Yan Li; Chien-Yuan E Lin; Jy-Kang Liou; Jiing-Feng Lirng; Feng Liu; Joanna R Long; Ruoyun Ma; Celine Maes; Marta Moreno-Ortega; Scott O Murray; Sean Noah; Ralph Noeske; Michael D Noseworthy; Georg Oeltzschner; Eric C Porges; James J Prisciandaro; Nicolaas A J Puts; Timothy P L Roberts; Markus Sack; Napapon Sailasuta; Muhammad G Saleh; Michael-Paul Schallmo; Nicholas Simard; Diederick Stoffers; Stephan P Swinnen; Martin Tegenthoff; Peter Truong; Guangbin Wang; Iain D Wilkinson; Hans-Jörg Wittsack; Adam J Woods; Hongmin Xu; Fuhua Yan; Chencheng Zhang; Vadim Zipunnikov; Helge J Zöllner; Richard A E Edden; Peter B Barker
Journal:  Radiology       Date:  2020-02-11       Impact factor: 11.105

Review 7.  Proton magnetic resonance spectroscopy: clinical applications in patients with brain lesions.

Authors:  Sérgio Luiz Ramin; Waldir Antonio Tognola; Antonio Ronaldo Spotti
Journal:  Sao Paulo Med J       Date:  2004-06-28       Impact factor: 1.044

8.  Comparison of 1.5T and 3T 1H MR spectroscopy for human brain tumors.

Authors:  Ji-hoon Kim; Kee-Hyun Chang; Dong Gyu Na; In Chan Song; Seung Ja Kim; Bae Ju Kwon; Moon Hee Han
Journal:  Korean J Radiol       Date:  2006 Jul-Sep       Impact factor: 3.500

9.  Multivoxel 1H-MR Spectroscopy Biometrics for Preoprerative Differentiation Between Brain Tumors.

Authors:  Faris Durmo; Anna Rydelius; Sandra Cuellar Baena; Krister Askaner; Jimmy Lätt; Johan Bengzon; Elisabet Englund; Thomas L Chenevert; Isabella M Björkman-Burtscher; Pia C Sundgren
Journal:  Tomography       Date:  2018-12

Review 10.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Pieter Wesseling; Daniel J Brat; Ian A Cree; Dominique Figarella-Branger; Cynthia Hawkins; H K Ng; Stefan M Pfister; Guido Reifenberger; Riccardo Soffietti; Andreas von Deimling; David W Ellison
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.